AstraZeneca PLC (AZN)vsHealthcare Triangle Inc (HCTI)
AZN
AstraZeneca PLC
$190.95
-0.70%
HEALTHCARE · Cap: $284.30B
HCTI
Healthcare Triangle Inc
$1.81
-3.49%
HEALTHCARE · Cap: $4.44M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 301462% more annual revenue ($60.44B vs $20.04M). AZN leads profitability with a 17.2% profit margin vs -69.7%. HCTI trades at a lower P/E of 0.0x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
HCTI
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$190.95
$3.62 discount
Intrinsic value data unavailable for HCTI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 166.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -26.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : HCTI
The strongest argument for HCTI centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 166.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : HCTI
The primary concerns for HCTI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while HCTI is a hypergrowth play — different risk/reward profiles.
HCTI carries more volatility with a beta of 1.05 — expect wider price swings.
HCTI is growing revenue faster at 166.1% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 41/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Healthcare Triangle Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Healthcare Triangle, Inc. is a healthcare information technology company. The company is headquartered in Pleasanton, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?